中文｜English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R
Volume 41 Issue 9
Sep.  2025
Turn off MathJax
Article Contents
Article Navigation >  Journal of Clinical Hepatology  > 2025  >  41(9): 1829-1836

Effect of bioinformatics infrared liver disease therapeutic instrument on hepatic blood supply and liver fibrosis in patients with liver cirrhosis

DOI: 10.12449/JCH250918
  • 1.

    Department of Hepatology, Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine，Shanghai 201203，China

  • 2.

    Institute of Liver Diseases, Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine，Shanghai 201203，China

Research funding:

National Natural Science Foundation of China (81673780)

More Information
  • Corresponding author: ZHAO Changqing， cathy090909@126.com （ORCID： 0000-0002-7925-1835）
  • Received Date: 2024-12-31
  • Accepted Date: 2025-02-28
  • Published Date: 2025-09-25
    Abstract
  •   Objectives  To investigate the effect of the Bioinformatics Infrared Liver Therapeutic （BILT） instrument on portal vein blood flow， liver stiffness， and spleen stiffness in patients with liver cirrhosis， and to preliminarily explore the therapeutic effect and mechanism of the BILT instrument.  Methods  A total of 78 patients with compensated liver cirrhosis who attended the outpatient service or were hospitalized in Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine from October 2017 to December 2021 were enrolled， among whom 68 patients completed the 12-week treatment and were randomly divided into BILT group and simulated instrument group， with 34 patients in each group. In addition to basic treatment， the patients in the BILT group received irradiation with the BILT instrument， while those in the simulated instrument group received irradiation with the simulated instrument， for 30 minutes each time， twice a day； the course of treatment was 12 weeks for both groups. The two groups were compared in terms of laboratory markers （liver function， renal function， and routine blood test results）， liver and spleen ultrasound morphology， color Doppler blood flow detection （portal vein diameter， portal vein cross-sectional area， mean portal vein velocity， peak portal vein velocity， and mean portal vein flow）， and liver/spleen stiffness measurement before and after treatment. The independent samples t-test was used for comparison of normally distributed continuous data between two groups， and the non-parametric Mann-Whitney U rank sum test was used for comparison of non-normally distributed continuous data between two groups； the chi-square test was used for comparison of categorical data between groups. The paired samples correlation test was performed for the data before and after treatment within each group， and the paired samples t-test or the non-parametric Wilcoxon signed-rank test was performed for data with significant correlations.  Results  The paired samples correlation test showed no correlation in spleen attenuation parameter before and after treatment， suggesting that the results of spleen fat measured by FibroTouch could not be used for statistical analysis. After 12 weeks of treatment， compared with the control group， the treatment group had significantly greater increases in portal vein diameter， portal vein cross-sectional area， and mean portal vein flow and a significantly greater reduction in liver stiffness measurement （all P<0.05）. At week 0 before treatment and after 12 weeks of treatment， comparison of the immediate effect after 30 minutes of BILT irradiation showed that the treatment group had significant increases in portal vein diameter， portal vein cross-sectional area， mean portal vein velocity， and mean portal vein flow （all P<0.05）， while the control group showed no significant changes after irradiation （all P>0.05）； compared with the control group， the treatment group had significantly greater changes in all indicators except peak portal vein flow at week 0 （all P<0.05）. No adverse events were observed in either group.  Conclusion  The BILT instrument can improve portal vein blood flow in the liver and alleviate liver stiffness/fibrosis in patients with liver cirrhosis.

     

    • FullText(HTML)
  • loading
    • References(31)
  • [1]
    GINÈS P, KRAG A, ABRALDES JG, et al. Liver cirrhosis[J]. Lancet, 2021, 398( 10308): 1359- 1376. DOI: 10.1016/S0140-6736(21)01374-X.
    [2]
    GBD 2017 Cirrhosis Collaborators. The global, regional, and national burden of cirrhosis by cause in 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017[J]. Lancet Gastroenterol Hepatol, 2020, 5( 3): 245- 266
    [3]
    ASRANI SK, DEVARBHAVI H, EATON J, et al. Burden of liver diseases in the world[J]. J Hepatol, 2019, 70( 1): 151- 171. DOI: 10.1016/j.jhep.2018.09.014.
    [4]
    IWAO T, TOYONAGA A, OHO K, et al. Value of doppler ultrasound parameters of portal vein and hepatic artery in the diagnosis of cirrhosis and portal hypertension[J]. Am J Gastroenterol, 1997, 92( 6): 1012- 1017.
    [5]
    ANNET L, MATERNE R, DANSE E, et al. Hepatic flow parameters measured with MR imaging and Doppler US: Correlations with degree of cirrhosis and portal hypertension[J]. Radiology, 2003, 229( 2): 409- 414. DOI: 10.1148/radiol.2292021128.
    [6]
    Chinese Society of Hepatology, Chinese Medical Association. Chinese guidelines on the management of liver cirrhosis[J]. J Clin Hepatol, 2019, 35( 11): 2408- 2425. DOI: 10.3969/j.issn.1001-5256.2019.11.006.

    中华医学会肝病学分会. 肝硬化诊治指南[J]. 临床肝胆病杂志, 2019, 35( 11): 2408- 2425. DOI: 10.3969/j.issn.1001-5256.2019.11.006.
    [7]
    ZHAO ZM, ZHU CW, HUANG JQ, et al. Efficacy and safety of Fuzheng Huayu tablet on persistent advanced liver fibrosis following 2 years entecavir treatment: A single arm clinical objective performance criteria trial[J]. J Ethnopharmacol, 2022, 298: 115599. DOI: 10.1016/j.jep.2022.115599.
    [8]
    SHI K, LIU Y, WANG XJ, et al. Adjuvant fuzheng Huayu capsule reduces the incidence of hepatocellular carcinoma in patients with hepatitis B-caused cirrhosis[J]. Evid Based Complement Alternat Med, 2020, 2020: 8826091. DOI: 10.1155/2020/8826091.
    [9]
    RONG GH, CHEN YP, YU ZJ, et al. Synergistic effect of Biejia-Ruangan on fibrosis regression in patients with chronic hepatitis B treated with entecavir: A multicenter, randomized, double-blind, placebo-controlled trial[J]. J Infect Dis, 2022, 225( 6): 1091- 1099. DOI: 10.1093/infdis/jiaa266.
    [10]
    JI D, CHEN Y, BI JF, et al. Entecavir plus Biejia-Ruangan compound reduces the risk of hepatocellular carcinoma in Chinese patients with chronic hepatitis B[J]. J Hepatol, 2022, 77( 6): 1515- 1524. DOI: 10.1016/j.jhep.2022.07.018.
    [11]
    LIU YQ, ZHANG C, LI JW, et al. An-Luo-Hua-Xian pill improves the regression of liver fibrosis in chronic hepatitis B patients treated with entecavir[J]. J Clin Transl Hepatol, 2023, 11( 2): 304- 313. DOI: 10.14218/JCTH.2022.00091.
    [12]
    PANG XF. Non-thermal biological effect of infrared light absorbed by living systems[J]. Physics, 2001, 30( 9): 525- 532. DOI: 10.3321/j.issn: 0379-4148.2001.09.002.

    庞小峰. 生命体吸收的红外光的非热生物效应的研究[J]. 物理, 2001, 30( 9): 525- 532. DOI: 10.3321/j.issn: 0379-4148.2001.09.002.
    [13]
    ZHAO CQ, XUE HM, GU HT, et al. Effects of computer bioinformation liver therapy instrument on normal human hepatic blood flow[J]. Chin J Integr Tradit West Med Liver Dis, 2004, 14( 5): 290- 291. DOI: 10.3969/j.issn.1005-0264.2004.05.013.

    赵长青, 薛惠明, 顾宏图, 等. 电脑生物信息肝病治疗仪对正常人肝血流的影响[J]. 中西医结合肝病杂志, 2004, 14( 5): 290- 291. DOI: 10.3969/j.issn.1005-0264.2004.05.013.
    [14]
    SUN JY, JIANG YY, SUN FX. Efficacy of BILT instrument in the treatment of chronic hepatitis and cirrhosis[J/OL]. Chin J Exp Clin Infect Dis Electron Version, 2008, 2( 3): 196- 198. DOI: 10.3969/j.issn.1674-1358.2008.03.014.

    孙静媛, 江宇泳, 孙凤霞. BILT肝病治疗仪辅助治疗慢性肝炎及肝硬化临床疗效观察[J/OL]. 中华实验和临床感染病杂志(电子版), 2008, 2( 3): 196- 198. DOI: 10.3969/j.issn.1674-1358.2008.03.014.
    [15]
    HE JS, ZHOU DQ, GAO H, et al. Clinical research on liver cirrbosis induced by hepatitis treated by medical instrument on hepatic diseases of type I DSG[J]. Chin J Integr Tradit West Med Liver Dis, 2005, 15( 4): 234- 236. DOI: 10.3969/j.issn.1005-0264.2005.04.016.

    贺劲松, 周大桥, 高辉, 等. DSG-Ⅰ型生物信息肝病治疗仪对肝炎肝硬化的影响[J]. 中西医结合肝病杂志, 2005, 15( 4): 234- 236. DOI: 10.3969/j.issn.1005-0264.2005.04.016.
    [16]
    CHEN LM, YE WH, WANG LJ, et al. Clinical study of biological information infrared liver disease therapeutic instrument in the treatment of patients with liver cirrhosis[J]. Chin J Clin Infect Dis, 2008, 1( 3): 170- 172.

    陈黎明, 叶文华, 王陆军, 等. 生物信息红外肝病治疗仪治疗肝硬化患者的临床研究[J]. 中华临床感染病杂志, 2008, 1( 3): 170- 172.
    [17]
    YE PY, CHEN XR. Treatment of posthepatitis cirrhosis with DSG-Ⅰliver disease therapy instrument and drugs[J]. Zhejiang J Integr Tradit Chin West Med, 2008, 18( 4): 229- 230. DOI: 10.3969/j.issn.1005-4561.2008.04.019.

    叶佩燕, 陈晓蓉. DSG-Ⅰ型肝病治疗仪合药物治疗肝炎后肝硬化[J]. 浙江中西医结合杂志, 2008, 18( 4): 229- 230. DOI: 10.3969/j.issn.1005-4561.2008.04.019.
    [18]
    HUANG JR, SHI WQ, ZHU JZ, et al. Chronic hepatitis B and liver cirrhosis treat with medical instrument of DSG type I for hepatic diseases[J]. Drug Eval, 2007, 4( 1): 37- 39.

    黄建荣, 施维群, 朱菊珍, 等. DSG-I型电脑肝病治疗仪治疗慢性乙型肝炎和肝炎肝硬化[J]. 药品评价, 2007, 4( 1): 37- 39.
    [19]
    Chinese Society of Infectious and Parasitic Diseases, Chinese Society of Hepatology, Chinese Medical Association. Protocols for the prevention and treatment of viral hepatitis[J]. Chin J Infect Dis, 2001, 19( 1): 56- 62. DOI: 10.3760/cma.j.issn.1671-7600.2001.01.025.

    中华医学会传染病与寄生虫病学分会, 中华医学会肝病学分会. 病毒性肝炎防治方案[J]. 中华传染病杂志, 2001, 19( 1): 56- 62 DOI: 10.3760/cma.j.issn.1671-7600.2001.01.025.
    [20]
    Chinese Medical Association. Clinical diagnosis and treatment guidelines-digestive system diseases volume[M]. Beijing: People’s Medical Publishing House, 2005: 83- 86.

    中华医学会. 临床诊疗指南-消化系统疾病分册[M]. 北京: 人民卫生出版社, 2005: 83- 86.
    [21]
    LIU YY. Medical statistics(2nd edition)[M]. Beijing: Higher Education Press, 2004: 313.

    刘勇勇. 医学统计学(第二版)[M]. 北京: 高等教育出版社, 2004: 313.
    [22]
    Chinese Society of Infectious Diseases, Chinese Medical Association, Expert Committee for Prevention and Management of Liver Inflammation. Consensus statement by the expert committee for prevention and management of liver inflammation in China[J]. Chin J Pract Intern Med, 2014, 34( 2): 152- 162.

    中华医学会感染病学分会, 肝脏炎症及其防治专家共识专家委员会. 肝脏炎症及其防治专家共识[J]. 中国实用内科杂志, 2014, 34( 2): 152- 162.
    [23]
    Chinese Society of Ultrasound in Medicine, Oncology Intervention Committee of Chinese Research Hospital Society, National Health Commission Capacity Building and Continuing Education Expert Committee on Ultrasonic Diagnosis. Guideline for ultrasonic diagnosis of liver diseases[J]. J Clin Hepatol, 2021, 37( 8): 1770- 1785. DOI: 3969/j.issn.1001-5256.2021.08.007.

    中华医学会超声医学分会, 中国研究型医院学会肿瘤介入专业委员会, 国家卫生和健康委员会能力建设和继续教育中心超声医学专家委员会. 肝病超声诊断指南[J]. 临床肝胆病杂志, 2021, 37( 8): 1770- 1785. DOI: 10.3969/j.issn.1001-5256.2021.08.007.
    [24]
    Chinese Foundation for Hepatitis Prevention and Control; Chinese Society of Infectious Disease and Chinese Society of Hepatology, Chinese Medical Association; Liver Disease Committee of Chinese Research Hospital Association. Consensus on clinical application of transient elastography detecting liver fibrosis: a 2018 update[J]. Chin J Hepatol, 2019, 27( 3): 182- 191. DOI: 10.3760/cma.j.issn.1007-3418.2019.03.004.

    中国肝炎防治基金会, 中华医学会感染病学分会, 中华医学会肝病学分会和中国研究型医院学会肝病专业委员会. 瞬时弹性成像技术诊断肝纤维化专家共识(2018年更新版)[J]. 中华肝脏病杂志, 2019, 27( 3): 182- 191. DOI: 10.3760/cma.j.issn.1007-3418.2019.03.004.
    [25]
    ZHU L, YANG JR, HE LL, et al. Advances on the application of transient elastography in the diagnosis of liver fibrosis[J/CD]. Chin J Liver Dis(Electronic Version), 2023, 15( 3): 16- 22. DOI: 10.3969/j.issn.1674-7380.2023.03.003.

    朱璐, 杨君茹, 何玲玲, 等. 瞬时弹性成像在肝纤维化诊断中的应用研究进展[J/CD]. 中国肝脏病杂志(电子版), 2023, 15( 3): 16- 22. DOI: 10.3969/j.issn.1674-7380.2023.03.003.
    [26]
    LIU JQ, MENG FK, DING HG, et al. Current research status of spleen stiffness measurement in predicting portal hypertension and its complications in patients with liver cirrhosis[J]. J Clin Hepatol, 2023, 39( 5): 1184- 1190. DOI: 10.3969/j.issn.1001-5256.2023.05.029.

    刘积庆, 孟繁坤, 丁惠国, 等. 脾脏硬度预测肝硬化患者门静脉高压及其并发症的研究现状[J]. 临床肝胆病杂志, 2023, 39( 5): 1184- 1190. DOI: 10.3969/j.issn.1001-5256.2023.05.029.
    [27]
    GUAN YB. Clinical experience of GUAN Youbo[M]. Beijing: People’s Medical Publishing House, 1979: 131- 137.

    关幼波. 关幼波临床经验选[M]. 北京: 人民卫生出版社, 1979: 131- 137.
    [28]
    ZHANG Q, LIU P, ZHANG HW, et al. Study on the patterns of TCM syndrome differentiation of 900 patients with posthepatitic cirrhosis[J]. Chin J Integr Tradit West Med, 2006, 26( 8): 694- 697.

    张琴, 刘平, 章浩伟, 等. 900例肝炎后肝硬化中医证候判别模式的研究[J]. 中国中西医结合杂志, 2006, 26( 8): 694- 697.
    [29]
    GU J, HONG JH, XU LM, et al. Effects of“fuzheng Huayu capsule” on portal hemodynamics in patients with liver cirrhosis[J]. Shanghai J Tradit Chin Med, 2005, 39( 11): 31- 32. DOI: 10.16305/j.1007-1334.2005.11.014.

    顾杰, 洪嘉禾, 徐列明, 等. 扶正化瘀胶囊对肝硬化患者门脉血流动力学的影响[J]. 上海中医药杂志, 2005, 39( 11): 31- 32. DOI: 10.16305/j.1007-1334.2005.11.014.
    [30]
    XIAO DH, GU J, CAI H, et al. A randomized placebo-controlled multicentre study of Fuzhenghuayu capsule for prevention of oesophageal variceal bleeding in patients with liver cirrhosis[J]. Chin J Hepatol, 2014, 22( 8): 594- 599.

    肖定洪, 顾杰, 蔡虹, 等. 扶正化瘀胶囊预防肝硬化患者食管静脉曲张破裂出血的随机对照多中心临床研究[J]. 中华肝脏病杂志, 2014, 22( 8): 594- 599.
    [31]
    GE XJ, ZHAO CQ, XU LM. Effect of Fuzheng Huayu capsules on survival rate of patients with liver cirrhosis[J]. Chin J Hepatol, 2017, 25( 11): 834- 840.

    戈雪婧, 赵长青, 徐列明. 扶正化瘀胶囊对肝硬化患者生存率的影响[J]. 中华肝脏病杂志, 2017, 25( 11): 834- 840.
    • Relative Articles
    • Supplements(0)
    • Cited By
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Tables(3)

    Get Citation
    PDF
    XML

    Article Metrics

    Article views (123) PDF downloads(15) Cited by()
    Proportional views
    Related
        

    The first journal specializing in hepatobiliary and pancreatic diseases in China

    Supervisor：Ministry of Education of the People's Republic of China

    Sponsor：Jilin University

    Academic Support: Chinese Society of Hepatology，Chinese Medical Association

    Address: 461 Xinjiang Road, Changchun

    Submit：0431-88782044

    Peer review：0431-88783542

    Email：lcgdb@vip.163.com

    About Journal

    Submission Guideline

    Journal Online

    Hepatobiliary College

    Guidelines

    YesterdayIP[]YesterdayPV[]TodayIP[]TodayPV[]Online[]

    Website Design © 2020 Editorial Board of Journal of Clinical Hepatology 吉ICP备10000617号-1 Supported by: Beijing Renhe Information Technology Co. Ltd  

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return